Class II · ModerateRecall completed
Lyrica CR (pregabalin) extended release tablets
Could cause temporary or reversible harm; serious harm is unlikely.
Does this affect you?
Check your lot numberLot #: DN5396, EP9726, EK2417, Exp. Date August 2022
Where it was soldNationwide within the United States
Find the lot number printed on your box or bottle. If it matches — and you take this medicine — call your pharmacist. Don't stop a prescribed medicine on your own.
What happened
Failed Dissolution Specifications
What to do
- Check the lot number and expiry on your medicine against the recall above.
- Talk to your pharmacist or doctor before changing anything — don't stop on your own.
- Report any problems to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
Who makes it
| Distributed by / for | Parke-Davis Division of Pfizer Inc., NY, NY 10017 |
| NDC | 0071-1029-01 |
Show the full FDA record
| Full product label | Lyrica CR (pregabalin) extended release tablets, 330 mg, 30-count bottles, Rx only, Distributed by Parke-Davis Division of Pfizer Inc., NY, NY 10017, NDC 0071-1029-01 |
| Recalling firm | Viatris |
| Distribution | Nationwide within the United States |
| Quantity | 9,515 bottles |
| Recall initiated | 2021-08-23 |
| Report date | 2021-10-06 |
| Recall completed | 2022-09-07 |
| Recall number | D-0851-2021 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Morgantown WV United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗
This is public FDA recall information, not medical advice. A recall does not always mean your specific bottle is affected. Never stop a prescribed medicine without asking your pharmacist or doctor.